logo
logo
ICON Public Limited Company

ICON Public Limited Company

NASDAQ•ICLR
CEO: Dr. Steven A. Cutler MBA, Ph.D.
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1998-05-15
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.
連絡先情報
South County Business Park, Leopardstown, Dublin, D18 X5R3, Ireland
353-1-291-2000
www.iconplc.com
時価総額
$6.11B
PER (TTM)
10.3
20
配当利回り
--
52週高値
$211.00
52週安値
$66.58
52週レンジ
9%
順位32Top 23.6%
4.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$2.04B+0.63%
直近4四半期の推移

EPS

$0.03-98.72%
直近4四半期の推移

フリーCF

$351.89M-2.07%
直近4四半期の推移

2024 Annual 決算ハイライト

主なハイライト

Income from Operations Surges Income from operations increased 14.8% to 1.10B USD; operating margin expanded significantly to 13.3% from 11.8% in 2023.
Revenue Growth Continues Globally Revenue increased 2.0% to 8.28B USD in 2024, driven by acquisitions and organic growth across US, Europe, and Rest of World.
Net Debt Significantly Reduced Total net debt decreased 9.3% to 3.43B USD from 3.78B USD, reflecting substantial mandatory and voluntary principal repayments.
Operating Cash Flow Strong Net cash provided by operating activities increased 10.8% to 1.29B USD, primarily due to favorable changes in working capital timing.

リスク要因

UPO Conversion Rate Slows Unsatisfied Performance Obligation (UPO) reached 15.9B USD, but only 47% is expected to convert to revenue in the next 12 months.
Restructuring Charges Double Restructuring charges increased 103.0% to 92.1M USD in 2024, reflecting workforce reduction and office consolidation programs.
Variable Interest Rate Exposure Fluctuations in interest rates adversely affect results; 27% of outstanding debt remains subject to variable interest rates.
Cybersecurity and System Failures System failures, security breaches, or cyber attacks could materially limit operations and adversely affect financial results and reputation.

見通し

Accelerating Clinical Research with AI Focus on AI Centre of Excellence to accelerate trials, optimize resources, and ensure compliance while upholding data privacy standards.
Expanding Patient-Centric Trials Continued investment in Accellacare network and decentralized trials to improve patient recruitment and retention globally.
Increased Share Buyback Capacity Board authorized additional buyback program up to 750.0M USD, allowing total repurchase capacity of 1.0B USD.
Commitment to Emissions Reduction SBTi validated near-term targets: 61.2% Scope 1/2 GHG reduction by FY2028 from FY2019 base year.

同業比較

売上高 (TTM)

Fresenius Medical Care AGFMS
$21.68B
+2.1%
Universal Health Services, Inc.UHS
$16.99B
+10.2%
Smith & Nephew plcSNN
$11.61B
+9.9%

粗利益率 (最新四半期)

Neurocrine Biosciences, Inc.NBIX
97.8%
-0.5pp
Universal Health Services, Inc.UHS
90.8%
+0.6pp
Smith & Nephew plcSNN
70.6%
+0.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EXAS$19.61B-19.8-40.4%43.0%
RPRX$19.22B25.010.6%0.0%
ILMN$17.49B20.633.7%44.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
0.0%
緩やかな成長
4四半期純利益CAGR
-79.2%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月18日
|
EPS:$3.32
|
売上高:-
財務レポート
財務データ
全年度
  • Form 20-F - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月21日|
    売上高: $8.28B+2.0%
    |
    EPS: $9.60+28.7%
    予想を下回る
  • Form 20-F - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月23日|
    売上高: $8.12B+4.9%
    |
    EPS: $7.46+20.3%
    予想を下回る
  • Form 20-F - FY 2022

    会計期末: 2022年12月31日|提出日: 2023年2月24日|
    売上高: $7.74B+41.2%
    |
    EPS: $6.20+171.9%
    予想を下回る
  • Form 20-F - FY 2021

    会計期末: 2021年12月31日|提出日: 2022年3月1日|
    売上高: $5.48B+95.9%
    |
    EPS: $2.28-63.8%
    予想を下回る
  • Form 20-F - FY 2020

    会計期末: 2020年12月31日|提出日: 2021年2月24日|
    売上高: $2.80B-0.3%
    |
    EPS: $6.29-8.2%
    予想通り